Tuberculosis Research and Treatment / 2016 / Article / Tab 3

Research Article

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States

Table 3

Summary of 20 discordant results for detection of EMB resistance between PHL and CDC.

Number of samplesPHL growth-based DST resultPHL growth-based DST methodembB mutation detected by CDC’s MDDRCDC’s agar proportion result

1Susceptible BACTEC 460 and agar proportion Asn296Tyr Resistant
1Susceptible MGIT 960Met306Ile Resistant
1Susceptible BACTEC 460 and agar proportion Met306Ile Resistant
3Susceptible MGIT 960Met306Val Resistant
1SusceptibleBACTEC 460Met306ValResistant
1ResistantMGIT 960Glu378AlaSusceptible
2SusceptibleMGIT 960Gly406CysResistant
1SusceptibleNot performed in-houseGly406SerResistant
3ResistantMGIT 960NoneSusceptible
5SusceptibleMGIT 960NoneResistant
1SusceptibleNot performed in-houseNoneResistant

PHL: public health laboratory; DST: drug susceptibility testing; CDC: Centers for Disease Control and Prevention; MDDR: molecular detection of drug resistance.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.